Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · Real-Time Price · USD
5.50
+0.18 (3.38%)
At close: Apr 17, 2025, 4:00 PM
5.49
-0.01 (-0.18%)
After-hours: Apr 17, 2025, 7:27 PM EDT
Recursion Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Recursion Pharmaceuticals stock have an average target of 8.20, with a low estimate of 6.00 and a high estimate of 11. The average target predicts an increase of 49.09% from the current stock price of 5.50.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Recursion Pharmaceuticals stock from 5 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 3 | 3 | 3 | 2 | 2 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 4 | 4 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold Maintains $10 → $8 | Hold | Maintains | $10 → $8 | +45.45% | Apr 10, 2025 |
| Needham | Needham | Strong Buy Reiterates $11 | Strong Buy | Reiterates | $11 | +100.00% | Apr 8, 2025 |
| Leerink Partners | Leerink Partners | Hold Maintains $7 → $6 | Hold | Maintains | $7 → $6 | +9.09% | Feb 28, 2025 |
| Needham | Needham | Strong Buy Reiterates $11 | Strong Buy | Reiterates | $11 | +100.00% | Feb 6, 2025 |
| Keybanc | Keybanc | Buy Maintains $12 → $10 | Buy | Maintains | $12 → $10 | +81.82% | Jan 8, 2025 |
Financial Forecast
Revenue This Year
92.55M
from 58.84M
Increased by 57.30%
Revenue Next Year
136.94M
from 92.55M
Increased by 47.96%
EPS This Year
-1.72
from -1.69
EPS Next Year
-1.49
from -1.72
Revenue Forecast
| Revenue | 2025 | 2026 |
|---|---|---|
| High | 183.8M | 257.6M |
| Avg | 92.6M | 136.9M |
| Low | 27.5M | 35.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 |
|---|---|---|
| High | 212.3% | 178.4% |
| Avg | 57.3% | 48.0% |
| Low | -53.2% | -61.5% |
EPS Forecast
| EPS | 2025 | 2026 |
|---|---|---|
| High | -1.11 | -0.97 |
| Avg | -1.72 | -1.49 |
| Low | -3.04 | -2.55 |
EPS Growth
| EPS Growth | 2025 | 2026 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.